nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.11.2016 | Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation

verfasst von: Kevin G. Burfeind, Vijayshree Yadav, Daniel L. Marks

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Signs and symptoms of multiple sclerosis are usually attributed to demyelinating lesions in the spinal cord or cerebral cortex. The hypothalamus is a region that is often overlooked yet controls many important homeostatic functions, including those that are perturbed in multiple sclerosis. In this review we discuss how hypothalamic dysfunction may contribute to signs and symptoms in people with multiple sclerosis. While dysfunction of the hypothalamic-pituitary-adrenal axis is common in multiple sclerosis, the effects and mechanisms of this dysfunction are not well understood. We discuss three hypothalamic mechanisms of fatigue in multiple sclerosis: (1) general hypothalamic-pituitary-adrenal axis hyperactivity, (2) disordered orexin neurotransmission, (3) abnormal cortisol secretion. We then review potential mechanisms of weight dysregulation caused by hypothalamic dysfunction. Lastly, we propose future studies and therapeutics to better understand and treat hypothalamic dysfunction in multiple sclerosis. Hypothalamic dysfunction appears to be common in multiple sclerosis, yet current studies are underpowered and contradictory. Future studies should contain larger sample sizes and standardize hormone and neuropeptide measurements.

Who gets MS? National MS Society. http://www.nationalmssociety.org/About-the-Society/MS-Prevalence. 2016.

Sbardella E, Petsas N, Tona F, Prosperini L, Raz E, Pace G, et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One. 2013;8(5):e63250. doi:10.1371/journal.pone.0063250.PubMedPubMedCentralCrossRef

Vita G, Carolina Fazio M, Milone S, Blandino A, Salvi L, Messina C. Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. J Neurol Sci. 1993;120(1):82–6. doi:10.1016/0022-510X(93)90029-X.

Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169(4):1384–7. doi:10.1097/01.ju.0000049644.27713.c8.PubMedCrossRef

Mirone L, Altomonte L, D’Agostino P, Zoli A, Barini A, Magaro M. A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol. 1996;15(1):15–9.PubMedCrossRef

Stasi C, Orlandelli E. Role of the brain-gut axis in the pathophysiology of Crohn’s disease. Dig Dis. 2008;26(2):156–66. doi:10.1159/000116774.PubMedCrossRef

Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev. 1999;79(1):1–71.PubMed

Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology. 2007;148(9):4217–25. doi:10.1210/en.2007-0017.PubMedCrossRef

Shibata M. Hypothalamic neuronal responses to cytokines. Yale J Biol Med. 1990;63(2):147–56.PubMedPubMedCentral

10.

McCann SM, Kimura M, Karanth S, Yu WH, Mastronardi CA, Rettori V. The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Ann N Y Acad Sci. 2000;917:4–18.PubMedCrossRef

11.

Burfeind KG, Michaelis KA, Marks DL. The central role of hypothalamic inflammation in the acute illness response and cachexia. Semin Cell Dev Biol. 2016;54:42–52. doi:10.1016/j.semcdb.2015.10.038.PubMedCrossRef

12.

Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014;5:88. doi:10.3389/fphys.2014.00088.PubMedPubMedCentralCrossRef

13.

Imrich R, Rovensky J. Hypothalamic-pituitary-adrenal axis in rheumatoid arthritis. Rheum Dis Clin N Am. 2010;36(4):721–7. doi:10.1016/j.rdc.2010.09.003.CrossRef

14.

Lovelock JD, Coslet S, Johnson M, Rich S, Gomberg-Maitland M. Relative adrenal insufficiency in severe congestive heart failure with preserved systolic function: a case report. J Cardiovasc Med. 2007;8(9):754–7. doi:10.2459/JCM.0b013e328011c256 (Hagerstown, Md).CrossRef

15.

Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Scholmerich J, et al. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis. Eur J Gastroenterol Hepatol. 2003;15(5):495–501. doi:10.1097/01.meg.0000059115.41030.e0.PubMed

16.

Dorfman MD, Thaler JP. Hypothalamic inflammation and gliosis in obesity. Curr Opin Endocrinol Diabetes Obes. 2015;22(5):325–30. doi:10.1097/med.0000000000000182.PubMedPubMedCentralCrossRef

17.

Ysrraelit MC, Gaitan MI, Lopez AS, Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology. 2008;71(24):1948–54. doi:10.1212/01.wnl.0000336918.32695.6b.PubMedCrossRef

18.

Michelson D, Stone L, Galliven E, Magiakou MA, Chrousos GP, Sternberg EM, et al. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab. 1994;79(3):848–53. doi:10.1210/jcem.79.3.8077372.PubMed

19.

Then Bergh F, Kumpfel T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology. 1999;53(4):772–7.PubMedCrossRef

20.

Reder AT, Makowiec RL, Lowy MT. Adrenal size is increased in multiple sclerosis. Arch Neurol. 1994;51(2):151–4.PubMedCrossRef

21.

Huitinga I, De Groot CJ, Van der Valk P, Kamphorst W, Tilders FJ, Swaab DF. Hypothalamic lesions in multiple sclerosis. J Neuropathol Exp Neurol. 2001;60(12):1208–18.PubMedCrossRef

22.

Melief J, de Wit SJ, van Eden CG, Teunissen C, Hamann J, Uitdehaag BM, et al. HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. Acta Neuropathol. 2013;126(2):237–49. doi:10.1007/s00401-013-1140-7.PubMedCrossRef

23.

Nagaraj K, Taly AB, Gupta A, Prasad C, Christopher R. Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life. J Neurosci Rural Pract. 2013;4(3):278–82. doi:10.4103/0976-3147.118774.PubMedPubMedCentralCrossRef

24.

Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol. 1988;45(4):435–7.PubMedCrossRef

25.

Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler. 2002;8(6):523–6.PubMedCrossRef

26.

Rosenberg JH, Shafor R. Fatigue in multiple sclerosis: a rational approach to evaluation and treatment. Curr Neurol Neurosci Rep. 2005;5(2):140–6.PubMedCrossRef

27.

Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler. 2008;14(8):1127–30. doi:10.1177/1352458508092807.PubMedPubMedCentralCrossRef

28.

Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol. 2004;61(4):525–8. doi:10.1001/archneur.61.4.525.PubMedCrossRef

29.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28. doi:10.1016/S0140-6736(12)61769-3.

30.

Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996;46(2):552–4.PubMedCrossRef

31.

Hoepner R, Faissner S, Salmen A, Gold R, Chan A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis. 2014;6:41–9. doi:10.4137/jcnsd.s14049.PubMedPubMedCentralCrossRef

32.

Cantor F. Central and peripheral fatigue: exemplified by multiple sclerosis and myasthenia gravis. PM R. 2010;2(5):399–405. doi:10.1016/j.pmrj.2010.04.012.

33.

Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18(4):314–25. doi:10.1016/j.bbi.2003.12.011.

34.

Murialdo G, Barreca A, Nobili F, Rollero A, Timossi G, Gianelli MV, et al. Dexamethasone effects on cortisol secretion in Alzheimer’s disease: some clinical and hormonal features in suppressor and nonsuppressor patients. J Endocrinol Investig. 2000;23(3):178–86. doi:10.1007/bf03343703.CrossRef

35.

Vreeburg SA, Hoogendijk WG, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry. 2009;66(6):617–26. doi:10.1001/archgenpsychiatry.2009.50.PubMedCrossRef

36.

Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain Behav Immun. 2016;52:98–105. doi:10.1016/j.bbi.2015.10.005.

37.

Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37(11):1583–92.PubMedCrossRef

38.

Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30(1):92–100. doi:10.1016/j.psyneuen.2004.06.003.PubMedCrossRef

39.

Generaal E, Vogelzangs N, Macfarlane GJ, Geenen R, Smit JH, Penninx BW, et al. Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders. BMC Musculoskelet Disord. 2014;15(1):1–11. doi:10.1186/1471-2474-15-227.CrossRef

40.

Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ. Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology. 2007;55(2):112–20. doi:10.1159/000104468.CrossRef

41.

Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351–62. doi:10.1056/nejm199505183322008.PubMedCrossRef

42.

Han KS, Kim L, Shim I. Stress and sleep disorder. Exp Neurobiol. 2012;21(4):141–50. doi:10.5607/en.2012.21.4.141.PubMedPubMedCentralCrossRef

43.

Gottschalk M, Kumpfel T, Flachenecker P, Uhr M, Trenkwalder C, Holsboer F, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 2005;62(2):277–80. doi:10.1001/archneur.62.2.277.PubMedCrossRef

44.

Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry. 2006;77(1):34–9. doi:10.1136/jnnp.2005.065805.PubMedPubMedCentralCrossRef

45.

Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003;38(5):701–13. doi:10.1016/S0896-6273(03)00331-3.

46.

Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996–10015.PubMed

47.

Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–81. doi:10.1038/nrn2092.PubMedCrossRef

48.

Fronczek R, van Geest S, Frölich M, Overeem S, Roelandse FWC, Lammers GJ, et al. Hypocretin (orexin) loss in Alzheimer’s disease. Neurobiol Aging. 2012;33(8):1642–50. doi:10.1016/j.neurobiolaging.2011.03.014.

49.

Long-Biao C, Bo-Wei L, Xiao-Hang J, Lin Z, Juan S. Progressive changes of orexin system in a rat model of 6-hydroxydopamineinduced Parkinson’s disease. Neurosci Bull. 2010;26(5):381–7. doi:10.1007/s12264-010-0410-9.CrossRef

50.

Irving EA, Harrison DC, Babbs AJ, Mayes AC, Campbell CA, Hunter AJ, et al. Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat. Neurosci Lett. 2002;324(1):53–6. doi:10.1016/S0304-3940(02)00176-3.

51.

Grossberg AJ, Zhu X, Leinninger GM, Levasseur PR, Braun TP, Myers Jr MG, et al. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci. 2011;31(31):11376–86. doi:10.1523/JNEUROSCI.2311-11.2011.PubMedPubMedCentralCrossRef

52.

Kato T, Kanbayashi T, Yamamoto K, Nakano T, Shimizu T, Hashimoto T, et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med. 2003;42(8):743–5.PubMedCrossRef

53.

Oka Y, Kanbayashi T, Mezaki T, Iseki K, Matsubayashi J, Murakami G, et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol. 2004;251(7):885–6. doi:10.1007/s00415-004-0442-z.PubMedCrossRef

54.

Nozaki H, Shimohata T, Kanbayashi T, Sagawa Y, Katada S, Satoh M, et al. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med. 2009;10(2):253–5. doi:10.1016/j.sleep.2007.11.022.PubMedCrossRef

55.

Küçükali Cİ, Haytural H, Benbir G, Coban A, Ulusoy C, Giriş M, et al. Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients. J Neurol Sci. 2014;346(1–2):353–5. doi:10.1016/j.jns.2014.08.041.

56.

Papuc E, Stelmasiak Z, Grieb P, Pawel G, Rejdak K. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci Lett. 2010;474(1):9–12. doi:10.1016/j.neulet.2010.02.062.PubMedCrossRef

57.

Constantinescu CS, Niepel G, Patterson M, Judd A, Braitch M, Fahey AJ, et al. Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol Sci. 2011;307(1-2):127–31. doi:10.1016/j.jns.2011.04.024.PubMedCrossRef

58.

Dalal MA, Schuld A, Haack M, Uhr M, Geisler P, Eisensehr I, et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology. 2001;56(12):1749–51.PubMedCrossRef

59.

Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96–104.PubMedCrossRef

60.

Boddum K, Hansen MH, Jennum PJ, Kornum BR. Cerebrospinal fluid hypocretin-1 (orexin-A) level fluctuates with season and correlates with day length. PLoS One. 2016;11(3):e0151288. doi:10.1371/journal.pone.0151288.PubMedPubMedCentralCrossRef

61.

Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, et al. Release of hypocretin (orexin) during waking and sleep states. J Neurosci. 2002;22(13):5282–6. 20026541.PubMed

62.

Dinneen S, Alzaid A, Miles J, Rizza R. Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. J Clin Invest. 1993;92(5):2283–90. doi:10.1172/jci116832.PubMedPubMedCentralCrossRef

63.

Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5(3):243–51.PubMedCrossRef

64.

Chapotot F, Gronfier C, Jouny C, Muzet A, Brandenberger G. Cortisol secretion is related to electroencephalographic alertness in human subjects during daytime wakefulness. J Clin Endocrinol Metab. 1998;83(12):4263–8. doi:10.1210/jcem.83.12.5326.PubMed

65.

do Lee Y, Kim E, Choi MH. Technical and clinical aspects of cortisol as a biochemical marker of chronic stress. BMB Rep. 2015;48(4):209–16.PubMedPubMedCentralCrossRef

66.

Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000.PubMedCrossRef

67.

Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 2013;30(Suppl):S163–70. doi:10.1016/j.bbi.2012.07.019.PubMedCrossRef

68.

Lara VP, Caramelli P, Teixeira AL, Barbosa MT, Carmona KC, Carvalho MG, et al. High cortisol levels are associated with cognitive impairment no-dementia (CIND) and dementia. Clin Chim Acta. 2013;423:18–22. doi:10.1016/j.cca.2013.04.013.

69.

Clow A, Hucklebridge F, Stalder T, Evans P, Thorn L. The cortisol awakening response: more than a measure of HPA axis function. Neurosci Biobehav Rev. 2010;35(1):97–103. doi:10.1016/j.neubiorev.2009.12.011.PubMedCrossRef

70.

Papadopoulos AS, Cleare AJ. Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2012;8(1):22–32. doi:10.1038/nrendo.2011.153.CrossRef

71.

Powell DJ, Liossi C, Moss-Morris R, Schlotz W. Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology. 2013;38(11):2405–22. doi:10.1016/j.psyneuen.2013.07.004.PubMedCrossRef

72.•

Powell DJ, Moss-Morris R, Liossi C, Schlotz W. Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis. Psychoneuroendocrinology. 2015;56:120–31. doi:10.1016/j.psyneuen.2015.03.010. Powell et al. investigated the relationship between circadian cortisol and fatigue in 76 individuals (38 RRMS and 38 healthy controls). They found that RRMS patients with fatigue had increased cortisol awakening response (CAR) compared to individuals without MS. This paper presents CAR as a solid measure of HPA axis function, and implicates hypothalamic dysfunction in fatigue in MS.PubMedCrossRef

73.

Knutsson U, Dahlgren J, Marcus C, Rosberg S, Bronnegard M, Stierna P, et al. Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab. 1997;82(2):536–40. doi:10.1210/jcem.82.2.3769.PubMed

74.

Burke CW. Biologically active cortisol in plasma of oestrogen-treated and normal subjects. Br Med J. 1969;2(5660):798–800.PubMedPubMedCentralCrossRef

75.

Turpeinen U, Hämäläinen E. Determination of cortisol in serum, saliva and urine. Best Pract Res Clin Endocrinol Metab. 2013;27(6):795–801. doi:10.1016/j.beem.2013.10.008.

76.

Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab. 2006;91(10):3725–45. doi:10.1210/jc.2006-0674.PubMedCrossRef

77.

Ng SM, Agwu JC, Dwan K. A systematic review and meta-analysis of Synacthen tests for assessing hypothalamic-pituitary-adrenal insufficiency in children. Arch Dis Child. 2016. doi:10.1136/archdischild-2015-308925.PubMed

78.

Jensen MA, Mortier L, Koh E, Keevil B, Hyttinen S, Hansen AM. An interlaboratory comparison between similar methods for determination of melatonin, cortisol and testosterone in saliva. Scand J Clin Lab Invest. 2014;74(5):454–61. doi:10.3109/00365513.2014.900693.PubMedCrossRef

79.

Alexandraki KI, Grossman AB. Is urinary free cortisol of value in the diagnosis of Cushing’s syndrome? Curr Opin Endocrinol Diabetes Obes. 2011;18(4):259–63. doi:10.1097/MED.0b013e3283487193.PubMedCrossRef

80.

Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of chronic stress: current status, future directions and unanswered questions. Psychoneuroendocrinology. 2012;37(5):589–601. doi:10.1016/j.psyneuen.2011.09.009.

81.

Thomson S, Koren G, Fraser LA, Rieder M, Friedman TC, Van Uum SH. Hair analysis provides a historical record of cortisol levels in Cushing’s syndrome. Exp Clin Endocrinol Diabetes. 2010;118(2):133–8. doi:10.1055/s-0029-1220771.PubMedCrossRef

82.••

Patejdl R, Penner IK, Noack TK, Zettl UK. Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev. 2016;15(3):210–20. doi:10.1016/j.autrev.2015.11.005 . Patejdl et al. described the differences between primary fatigue (caused by the disease itself) and secondary fatigue (resulting from other side effects of the disease or drugs) in MS. They summarize literature supporting the claim that damage to the CNS and/or cytokines derived from immune cells leads to neuroendocrine dysfunction and neuronal damage, which subsequently causes fatigue.

83.

Zellini F, Niepel G, Tench CR, Constantinescu CS. Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009;15(12):1442–9. doi:10.1177/1352458509350306.PubMedCrossRef

84.

Gershon AS, Margulies M, Gorczynski RM, Heathcote EJ. Serum cytokine values and fatigue in chronic hepatitis C infection. J Viral Hepat. 2000;7(6):397–402.PubMedCrossRef

85.

Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–11.PubMedCrossRef

86.

Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788–93. doi:10.1002/cncr.21234.PubMedCrossRef

87.

Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, et al. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol. 2011;136(5):696–704. doi:10.1309/ajcp7ubk8ibvmvnr.PubMedCrossRef

88.

Malekzadeh A, Van de Geer-Peeters W, De Groot V, Elisabeth Teunissen C, Beckerman H, Group T-AS. Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines? Dis Markers. 2015;2015:758314. doi:10.1155/2015/758314.PubMedPubMedCentralCrossRef

89.

Beurskens AJ, Bultmann U, Kant I, Vercoulen JH, Bleijenberg G, Swaen GM. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med. 2000;57(5):353–7.PubMedPubMedCentralCrossRef

90.

Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, Levasseur PR, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med. 2011;208(12):2449–63. doi:10.1084/jem.20111020.PubMedPubMedCentralCrossRef

91.

Schmidt FM, Weschenfelder J, Sander C, Minkwitz J, Thormann J, Chittka T, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015;10(3):e0121971. doi:10.1371/journal.pone.0121971.PubMedPubMedCentralCrossRef

92.

Khurana SR, Bamer AM, Turner AP, Wadhwani RV, Bowen JD, Leipertz SL, et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil. 2009;88(2):83–91. doi:10.1097/PHM.0b013e318194f8b5.PubMedCrossRef

93.•

Pinhas-Hamiel O, Livne M, Harari G, Achiron A. Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol. 2015;22(9):1275–9. doi:10.1111/ene.12738. Pinhas-Hamiel et al. reported a decreased prevalence of obesity in MS patients compared to the general population. However, these patients had high rates of abdominal obesity and metabolic syndrome. This highlights the shortcomings in using BMI as the sole measure of body composition. The findings from this paper suggest MS patients are vulnerable to metabolic dysregulation.PubMedCrossRef

94.

Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009;15(1):105–13. doi:10.1177/1352458508096680.PubMedCrossRef

95.

Marrie RA, Horwitz R, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011;124(2):135–41. doi:10.1111/j.1600-0404.2010.01436.x.PubMedCrossRef

96.

Garner DJ, Widrick JJ. Cross-bridge mechanisms of muscle weakness in multiple sclerosis. Muscle Nerve. 2003;27(4):456–64. doi:10.1002/mus.10346.PubMedCrossRef

97.

Kent-Braun JA, Ng AV, Castro M, Weiner MW, Gelinas D, Dudley GA, et al. Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. J Appl Physiol. 1997;83(6):1998–2004.PubMed

98.

Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int. 1997;61(2):129–33.PubMedCrossRef

99.

Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693–700. doi:10.1097/MCO.0b013e328312c37d.PubMedPubMedCentralCrossRef

100.

Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr. 2007;2(3):183–9.PubMedCrossRef

101.

Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne IJ. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring). 2006;14(12):2277–83. doi:10.1038/oby.2006.267.CrossRef

102.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi:10.1016/s1470-2045(10)70218-7.PubMedCrossRef

103.

Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–71.PubMedCrossRef

104.

Von Roenn JH, Roth EL, Craig R. HIV-related cachexia: potential mechanisms and treatment. Oncology. 1992;49 Suppl 2:50–4.

105.

Plauth M, Schutz ET. Cachexia in liver cirrhosis. Int J Cardiol. 2002;85(1):83–7.PubMedCrossRef

106.

Poehlman ET, Dvorak RV. Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71(2):650s–5s.PubMed

107.

Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93(6):2379–86.PubMedPubMedCentralCrossRef

108.

Kamalian N, Keesey RE, ZuRhein GM. Lateral hypothalamic demyelination and cachexia in a case of “malignant” multiple sclerosis. Neurology. 1975;25(1):25–30.PubMedCrossRef

109.

van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999;46(5):747–54.PubMedCrossRef

110.

A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. Can J Neurol Sci. 1987;14(3):273-8.

111.

Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985;12(03):251–4.PubMedCrossRef

112.

Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45(11):1956–61.PubMedCrossRef

113.

Pucci E, Branas P, D’Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007(1):Cd002818. doi:10.1002/14651858.CD002818.pub2.

114.

Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs. 2008;68(13):1803–39.PubMedCrossRef

115.

Wisor JP. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139. doi:10.3389/fneur.2013.00139.PubMedPubMedCentralCrossRef

116.

Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8(12):e81802. doi:10.1371/journal.pone.0081802.PubMedPubMedCentralCrossRef

117.

Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol. 2002;249(8):983–7. doi:10.1007/s00415-002-0765-6.PubMedCrossRef

118.

Rammohan K, Rosenberg J, Lynn D, Blumenfeld A, Pollak C, Nagaraja H. Efficacy and safety of modafinil (Provigil(®)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72(2):179–83. doi:10.1136/jnnp.72.2.179.PubMedPubMedCentralCrossRef

119.

Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285. doi:10.1155/2014/798285.PubMedPubMedCentral

120.

Dobryakova E, Genova HM, DeLuca J, Wylie GR. The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front Neurol. 2015;6:52. doi:10.3389/fneur.2015.00052.PubMedPubMedCentralCrossRef

121.

Yadav V, Bever Jr C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083–92. doi:10.1212/wnl.0000000000000250.PubMedPubMedCentralCrossRef

122.

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.PubMedCrossRef

123.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26. doi:10.1016/S0140-6736(03)14738-1.

124.

Fatemi I, Shamsizadeh A, Ayoobi F, Taghipour Z, Sanati MH, Roohbakhsh A, et al. Role of orexin-A in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2016;291:101–9. doi:10.1016/j.jneuroim.2016.01.001.PubMedCrossRef

125.

Equihua AC, De La Herrán-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol. 2013;4:163. doi:10.3389/fphar.2013.00163.PubMedPubMedCentralCrossRef

126.

Morairty SR, Revel FG, Malherbe P, Moreau J-L, Valladao D, Wettstein JG, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One. 2012;7(7):e39131. doi:10.1371/journal.pone.0039131.PubMedPubMedCentralCrossRef

127.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, et al. Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. J Clin Sleep Med. 2016 [Epub ahead of print].

128.

Panzica G, Melcangi RC. Structural and molecular brain sexual differences: a tool to understand sex differences in health and disease. Neurosci Biobehav Rev. 2016;67:2–8. doi:10.1016/j.neubiorev.2016.04.017.

Titel: Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation
verfasst von: Kevin G. Burfeind
Vijayshree Yadav
Daniel L. Marks
Publikationsdatum: 01.11.2016
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 11/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-016-0700-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Treatment of Epilepsy in the Elderly

Prevention of Epilepsy: Issues and Innovations

Headaches: a Review of the Role of Dietary Factors

Toward a Mechanistic Understanding of Epileptic Networks

Communication, Leadership, and Decision-Making in the Neuro-ICU